Healthcare provider profile · identity verified

James D Brinkruff, MD

Allopathic & Osteopathic Physicians|Internal Medicine · GREENFIELD, IN · NPI 1578657813

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show James D Brinkruff, MD received $108.01 in general payments during 2025 across 4 reported records.

Novo Nordisk Inc accounted for 60.3% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 4 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Shingrix.

GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Arexvy by this doctor in 2024.

GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Shingrix by this doctor in 2024.

GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Trelegy Ellipta by this doctor in 2024.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Ozempic by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$108.01

4 reported records · 3 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Novo Nordisk Inc	Unresolved — no canonical attribution shown	$65.11	60.3%	1	2025
Exact Sciences Corporation	Unresolved — no canonical attribution shown	$28.49	26.4%	2	2025
GlaxoSmithKline, LLC.	Unresolved — no canonical attribution shown	$14.41	13.3%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$108.01	4

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
Ozempic Normalized: ozempic	Drug	Novo Nordisk Inc	$65.11	1	2025
Source payment records 2025-05-07 · Novo Nordisk Inc · $65.11 · Open Payments source
The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit	Device	Exact Sciences Corporation	$14.49	1	2025
Source payment records 2025-10-01 · Exact Sciences Corporation · $14.49 · Open Payments source
SHINGRIX Normalized: shingrix	Biological	GlaxoSmithKline, LLC.	$14.41	1	2025
Source payment records 2025-11-19 · GlaxoSmithKline, LLC. · $14.41 · Open Payments source
Cologuard Collection Kit Normalized: cologuard collection kit	Device	Exact Sciences Corporation	$14.00	1	2025
Source payment records 2025-03-25 · Exact Sciences Corporation · $14.00 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
Ozempic ozempic	2025	Ozempic	2024	137	exact normalized	Medicare Part D
SHINGRIX shingrix	2025	Shingrix	2024	35	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference	2025	AREXVY open payments reported associated product	CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445	Arexvy · 2024 Exact normalized brand match · 1 Part D row	18	18
GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference	2025	SHINGRIX open payments reported associated product	CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452	Shingrix · 2024 Exact normalized brand match · 1 Part D row	35	34
GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference	2025	TRELEGY ELLIPTA open payments reported associated product	CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369	Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row	64	11
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Ozempic open payments reported associated product	CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076	Ozempic · 2024 Exact normalized brand match · 1 Part D row	137	23

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	550	156
Levothyroxine Sodium	Levothyroxine Sodium	433	121
Rosuvastatin Calcium	Rosuvastatin Calcium	365	101
Amlodipine Besylate	Amlodipine Besylate	313	87
Omeprazole	Omeprazole	296	89
Lisinopril	Lisinopril	293	85
Metformin Hcl	Metformin Hcl	268	78
Metoprolol Succinate	Metoprolol Succinate	248	66
Simvastatin	Simvastatin	205	61
Tamsulosin Hcl	Tamsulosin Hcl	195	64
Pantoprazole Sodium	Pantoprazole Sodium	170	44
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	165	42
Losartan Potassium	Losartan Potassium	165	48
Alprazolam	Alprazolam	156	26
Mounjaro	Tirzepatide	156	29
Alendronate Sodium	Alendronate Sodium	152	44
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	140	45
Prednisone	Prednisone	140	55
Meloxicam	Meloxicam	137	41
Ozempic	Semaglutide	137	23
Hydrochlorothiazide	Hydrochlorothiazide	136	40
Gabapentin	Gabapentin	130	34
Trazodone Hcl	Trazodone Hcl	127	39
Albuterol Sulfate Hfa	Albuterol Sulfate	125	43
Allopurinol	Allopurinol	123	36
Jardiance	Empagliflozin	119	31
Furosemide	Furosemide	112	32
Tramadol Hcl	Tramadol Hcl	112	31
Sertraline Hcl	Sertraline Hcl	110	32
Eliquis	Apixaban	104	33
Bupropion Xl	Bupropion Hcl	99	22
Pregabalin	Pregabalin	95	21
Clopidogrel	Clopidogrel Bisulfate	94	28
Metoprolol Tartrate	Metoprolol Tartrate	92	28
Montelukast Sodium	Montelukast Sodium	90	28
Trulicity	Dulaglutide	88	20
Fluoxetine Hcl	Fluoxetine Hcl	83	22
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	82	25
Pravastatin Sodium	Pravastatin Sodium	79	21
Duloxetine Hcl	Duloxetine Hcl	75	19
Atenolol	Atenolol	74	22
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	73	21
Olmesartan Medoxomil	Olmesartan Medoxomil	72	22
Citalopram Hbr	Citalopram Hydrobromide	70	19
Synthroid	Levothyroxine Sodium	65	20
Testosterone Cypionate	Testosterone Cypionate	65	13
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	64	11
Escitalopram Oxalate	Escitalopram Oxalate	63	18
Metformin Hcl Er	Metformin Hcl	63	16
Celecoxib	Celecoxib	61	16
Diclofenac Sodium	Diclofenac Sodium	61	24
Zolpidem Tartrate	Zolpidem Tartrate	59	15
Ezetimibe	Ezetimibe	57	18
Glimepiride	Glimepiride	55	18
Amitriptyline Hcl	Amitriptyline Hcl	54	18
Tizanidine Hcl	Tizanidine Hcl	54	19
Doxazosin Mesylate	Doxazosin Mesylate	52	15
Clonazepam	Clonazepam	51	suppressed
Soliqua 100-33	Insulin Glargine/Lixisenatide	51	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	50	14
Venlafaxine Hcl Er	Venlafaxine Hcl	50	suppressed
Estradiol	Estradiol	49	suppressed
Ondansetron Odt	Ondansetron	49	20
Quetiapine Fumarate	Quetiapine Fumarate	49	suppressed
Terbinafine Hcl	Terbinafine Hcl	49	14
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	48	13
Donepezil Hcl	Donepezil Hcl	48	15
Cephalexin	Cephalexin	47	25
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	46	12
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	45	17
Spironolactone	Spironolactone	44	13
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	43	suppressed
Myrbetriq	Mirabegron	43	14
Ramipril	Ramipril	43	12
Valsartan	Valsartan	42	11
Oxybutynin Chloride Er	Oxybutynin Chloride	41	13
Breo Ellipta	Fluticasone/Vilanterol	39	suppressed
Buspirone Hcl	Buspirone Hcl	39	suppressed
Butorphanol Tartrate	Butorphanol Tartrate	39	suppressed
Famotidine	Famotidine	39	13
Triamcinolone Acetonide	Triamcinolone Acetonide	39	26
Doxycycline Monohydrate	Doxycycline Monohydrate	38	16
Irbesartan	Irbesartan	37	11
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	37	16
Pioglitazone Hcl	Pioglitazone Hcl	36	11
Shingrix	Varicella-Zoster Ge/As01b/Pf	35	34
Carvedilol	Carvedilol	32	11
Mirtazapine	Mirtazapine	32	suppressed
Paroxetine Hcl	Paroxetine Hcl	32	suppressed
Fluticasone Propionate	Fluticasone Propionate	31	14
Diazepam	Diazepam	30	suppressed
Finasteride	Finasteride	29	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	29	suppressed
Memantine Hcl	Memantine Hcl	28	suppressed
Naproxen	Naproxen	28	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	28	22
Esomeprazole Magnesium	Esomeprazole Magnesium	27	suppressed
Farxiga	Dapagliflozin Propanediol	27	suppressed
Glipizide Er	Glipizide	27	suppressed
Benazepril Hcl	Benazepril Hcl	26	suppressed
Digoxin	Digoxin	26	suppressed
Nitroglycerin	Nitroglycerin	26	14
Lansoprazole	Lansoprazole	25	suppressed
Lorazepam	Lorazepam	25	suppressed
Raloxifene Hcl	Raloxifene Hcl	25	suppressed
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	24	24
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	24	11
Bisoprolol Fumarate	Bisoprolol Fumarate	24	suppressed
Fluconazole	Fluconazole	24	12
Nebivolol Hcl	Nebivolol Hcl	23	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	22	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	22	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	22	suppressed
Lovastatin	Lovastatin	22	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	22	suppressed
Potassium Chloride	Potassium Chloride	21	suppressed
Boostrix Tdap	Diphth,pertuss(Acell),tet Vac	20	20
Glipizide	Glipizide	20	suppressed
Medroxyprogesterone Acetate	Medroxyprogesterone Acetate	20	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	20	suppressed
Xarelto	Rivaroxaban	20	suppressed
Fenofibrate	Fenofibrate	19	suppressed
Fluocinonide	Fluocinonide	19	suppressed
Temazepam	Temazepam	19	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	18	18
Chlorthalidone	Chlorthalidone	18	suppressed
Flunisolide	Flunisolide	18	suppressed
Bupropion Hcl Sr	Bupropion Hcl	17	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	17	suppressed
Topiramate	Topiramate	17	suppressed
Varenicline Tartrate	Varenicline Tartrate	17	suppressed
Amlodipine-Atorvastatin	Amlodipine/Atorvastatin	16	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	16	suppressed
Lidocaine	Lidocaine	16	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	16	suppressed
Novolog Flexpen	Insulin Aspart	16	suppressed
Nystatin	Nystatin	16	suppressed
Ondansetron Hcl	Ondansetron Hcl	16	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	16	suppressed
Warfarin Sodium	Warfarin Sodium	16	suppressed
Armodafinil	Armodafinil	15	suppressed
Carbamazepine	Carbamazepine	15	suppressed
Incruse Ellipta	Umeclidinium Bromide	15	suppressed
Levetiracetam	Levetiracetam	15	suppressed
Risedronate Sodium	Risedronate Sodium	15	suppressed
Baclofen	Baclofen	14	suppressed
Cefuroxime	Cefuroxime Axetil	14	11
Gemfibrozil	Gemfibrozil	14	suppressed
Ipratropium Bromide	Ipratropium Bromide	14	suppressed
Lamotrigine	Lamotrigine	14	suppressed
Methylprednisolone	Methylprednisolone	14	14
Oxybutynin Chloride	Oxybutynin Chloride	14	suppressed
Spiriva Respimat	Tiotropium Bromide	14	suppressed
Aptiom	Eslicarbazepine Acetate	13	suppressed
Hydralazine Hcl	Hydralazine Hcl	13	suppressed
Methotrexate	Methotrexate Sodium	13	suppressed
Midodrine Hcl	Midodrine Hcl	13	suppressed
Morphine Sulfate Er	Morphine Sulfate	13	suppressed
Nifedipine Er	Nifedipine	13	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	13	suppressed
Armour Thyroid	Thyroid,pork	12	suppressed
Humalog Kwikpen U-100	Insulin Lispro	12	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	12	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	12	suppressed
Liothyronine Sodium	Liothyronine Sodium	12	suppressed
Morphine Sulfate	Morphine Sulfate	12	suppressed
Promethazine Hcl	Promethazine Hcl	12	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Acyclovir	Acyclovir	11	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Benazepril-Hydrochlorothiazide	Benazepril/Hydrochlorothiazide	11	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	11	suppressed
Dutasteride	Dutasteride	11	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	11	suppressed
Verapamil Hcl	Verapamil Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$108.01 · 4 records	Novo Nordisk Inc	Cologuard Collection Kit, Ozempic, SHINGRIX, The Cologuard Plus Collection Kit	4	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Ozempic play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error